Impact of Epstein-Barr virus co-infection on natural acquired Plasmodium vivax antibody response

Michelle H F Dias1, Luiz F F Guimarães1, Matheus G Barcelos1

  • 1Instituto René Rachou/FIOCRUZ Minas, Belo Horizonte, Minas Gerais, Brazil.

Insights

Epstein-Barr virus (EBV) co-infection may impact naturally acquired antibody responses to Plasmodium vivax malaria. Persistent EBV DNA in blood correlated with lower antibody levels to key malaria antigens, suggesting implications for immunity and vaccine development.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Tropical Medicine

Background:

  • Epstein-Barr virus (EBV) establishes lifelong B-cell infections.
  • EBV co-infection with Plasmodium falciparum is linked to Burkitt's Lymphoma.
  • The impact of EBV on malaria immunity, particularly against Plasmodium vivax, is understudied.

Purpose of the Study:

  • To investigate the influence of persistent Epstein-Barr virus (EBV) infection on naturally acquired antibody responses to Plasmodium vivax.
  • To assess if EBV co-infection affects immune responses to malaria vaccine candidates.

Main Methods:

  • Cross-sectional study with three surveys over 12 months in the Amazon.
  • Compared malaria-exposed individuals with persistent EBV DNA (PersVDNA) versus no detectable EBV DNA (NegVDNA).
  • Measured IgG antibodies to EBV antigens and P. vivax blood-stage antigens, including a novel DBPII immunogen (DEKnull-2).

Main Results:

  • Individuals with persistent EBV DNA showed significantly higher IgG antibodies to EBV viral capsid antigen (VCA-p18).
  • The PersVDNA group generally exhibited lower antibody levels to P. vivax antigens compared to the NegVDNA group.
  • Significantly lower antibody responses were observed in the PersVDNA group to the DEKnull-2 immunogen, associated with neutralizing antibodies.

Conclusions:

  • Persistent EBV DNA detection in semi-immune adults may impair long-term immune responses to P. vivax.
  • This finding suggests EBV co-infection could influence the efficacy of malaria vaccines targeting blood-stage antigens.
  • Further research is needed to understand the mechanisms by which EBV affects malaria immunity.
Abstract